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fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; hsCRP, high 
sensitivity C-reactive protein; IHD, ischemic heart disease; IQR, interquartile range; MMP, matrix 
metalloproteinase; NGAL, Neutrophil gelatinase-associated lipocalin; PREVEND, Prevention of Renal 
and Vascular End-stage Disease; PTCA, percutaneous transluminal coronary angioplasty; RBS, Rancho 
Bernardo Study; SD, standard deviation; SBP, systolic blood pressure; UAE, urine albumin excretion 
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ABSTRACT 
Background: Neutrophil gelatinase-associated lipocalin (NGAL), a novel biomarker of acute kidney 
injury, might play a role in the development of atherosclerotic cardiovascular disease (CVD). We 
aimed to assess the association of circulating NGAL with CVD risk. 
Materials and methods: Plasma NGAL concentrations were measured at baseline in 5,275 participants 
in the PREVEND prospective study. Hazard ratios (95% confidence intervals [CI]) for CVD were 
estimated.  
Results: After a median follow-up of 8.3 years, 338 participants developed first CVD events. Plasma 
NGAL was weakly to moderately correlated with several CVD risk markers. There was a non-linear 
relationship between NGAL and CVD risk. In analyses adjusted for established risk factors, the 
hazard ratio (95% CI) for CVD in a comparison of the top quartile versus bottom quartiles 1-2 of 
NGAL values was 1.35 (1.05-1.75; P=0.022), which was abrogated after additional adjustment for 
other potential confounders (mainly attributed to high sensitivity C-reactive protein) 1.20 (0.92-1.57; 
P=0.176). The association was considerably attenuated following further adjustment for renal function 
1.05 (0.79-1.40; P=0.745). The association between NGAL and CVD risk did not vary importantly in 
relevant clinical subgroups. 
Conclusion: Evidence suggests a non-linear association between NGAL and CVD risk, which is 
dependent on inflammation and renal function.  
 
Keywords: Neutrophil gelatinase-associated lipocalin; cardiovascular disease; risk factor; cohort study 
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1. Introduction 
Neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin-2 or oncogene 24p3, 
is a human protein that is mainly expressed by neutrophils and in low levels by various epithelial 
cells.[1-3]  The physiological functions of NGAL include involvement in the innate immune response 
to bacterial infection[4] and it also functions as a growth factor.[5] NGAL has emerged as a precise 
and sensitive novel biomarker for acute kidney injury (AKI);[6, 7] within two hours of an AKI, high 
levels of NGAL are secreted into the blood and urine.[6] NGAL measurements also have potential 
relevance for chronic kidney disease (CKD), nephropathy, and kidney transplant.[8, 9] Beyond the 
kidney, [10]emerging evidence suggests that NGAL may be implicated in the pathogenesis of 
atherosclerotic CVD. Recent data from both human studies and animal models have demonstrated 
NGAL to be highly expressed in thrombi and atherosclerotic plaques.[11-14] NGAL is also highly 
expressed in the heart[13] and elevated levels have been demonstrated in patients with heart failure, 
coronary heart disease or syndromes, and stroke.[15-17] A number of studies have also reported 
associations between elevated NGAL levels and poor outcomes (e.g., mortality, hospital re-
admissions, heart failure, major adverse cardiac events) in patients with pre-existing CVD or kidney 
disease.[18-23] The overall evidence suggests that NGAL may be involved in CVD development. 
However, because the existing studies were (i) mostly cross-sectional evaluations of clinical studies; 
(ii) conducted in animal models or in patients with pre-existing disease; or (iii) either not sufficiently 
powered or did not account adequately for potential confounders; the temporal nature of the 
relationship between circulating NGAL and risk of CVD is not certain. A limited number of 
population-based prospective studies have however reported associations between increased 
circulating levels of NGAL and increased risk of first cardiovascular events in the general 
population.[24, 25] Though these previous studies were elegantly analyzed, they had a number of 
limitations which included not assessing the nature of the dose-response relationship between 
circulating NGAL and CVD risk and whether the association is modified by relevant clinical 
characteristics. In this context, we aimed to investigate in greater detail than ever before, aspects of 
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the association such as the shape, nature, magnitude, and consistency of the prospective association 
between plasma NGAL and risk of first-onset CVD events using a population-based cohort of 5,275 
participants who were free from pre-existing CVD at baseline.  
2. Materials and methods 
2.1. Study design and population  
We conducted the current study according to STROBE (STrengthening the Reporting of 
OBservational studies in Epidemiology) guidelines for reporting observational studies in 
epidemiology (Supplementary material 1).[26] We employed the Prevention of Renal and Vascular 
End-stage Disease (PREVEND) study for this analysis. PREVEND is a general population-based 
prospective cohort study which was designed to explore the natural course of urinary albumin 
excretion (UAE) and its association with kidney disease and CVD. The study design and recruitment 
processes have been described previously.[27-29] The PREVEND cohort consists of a representative 
sample of men and women living in the city of Groningen in the Netherlands. The current cohort 
involved 6894 individuals aged 32-80 years who were invited for the second screening phase of the 
PREVEND study and who had baseline assessments performed between 2001 and 2003. For this 
analysis, we included participants without pre-existing CVD, renal disease, or malignancy at baseline. 
The current analysis involved 5275 participants with non-missing information on plasma NGAL, 
relevant covariates, and cardiovascular outcomes. The local ethics committee of the University 
Medical Center Groningen approved the study protocol. The study procedures were conducted 
according to the Declaration of Helsinki and written informed consent was obtained from all study 
participants.  
 
2.2. Measurement of NGAL and risk markers 
Baseline data on demographics, anthropometric measurements, lifestyle factors, and other 
cardiovascular risk markers were collected during two outpatient visits by study participants. Venous 
blood samples were obtained from study participants after an overnight fast and 15 minutes of rest 
prior to sample collection. Plasma samples were prepared by centrifugation at 4 ºC and samples stored 
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at -80 ºC until analysis. Plasma NGAL concentrations were measured using Gentian NGAL 
turbidimetric immunoassay (Gentian, Moss, Norway) applied on a Mindray BS-400 analyser 
(Mindray, Shenzhen, China). The Gentian NGAL assay was calibrated to the commercially available 
Bioporto NGAL Test, using the value transfer protocol as described by Blirup-Jensen et al.[30] In 
addition, the Gentian NGAL calibrator has been validated according to the Clinical and Laboratory 
Standards Institute guidelines, with external validation performed by individual laboratories.[31] 
Fasting plasma glucose (FPG) was measured by dry chemistry (Eastman Kodak, Rochester, New 
York). Total cholesterol, high density lipoprotein cholesterol (HDL-C), triglycerides, and high 
sensitivity C-reactive protein (hsCRP) were measured using standard protocols previously 
described.[32-36] Serum creatinine was determined by Kodak Ektachem dry chemistry (Eastman 
Kodak, Rochester, New York). Serum cystatin C concentrations were measured by Gentian Cystatin 
C Immunoassay (Gentian AS, Moss, Norway) on a Modular analyzer (Roche Diagnostics). Cystatin C 
was calibrated directly using the standard supplied by the manufacturer (traceable to the International 
Federation of Clinical Chemistry Working Group for Standardization of Serum Cystatin C).[37] The 
intra- and inter-assay coefficients of variation were <4.1% and <3.3%, respectively. UAE was 
estimated as the mean of two 24-hour urine collections and the concentration was determined by 
nephelometry (BNII; Dade Behring Diagnostic, Marburg, Germany). The Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) combined creatinine-cystatin C equation was used to 
calculate estimated glomerular filtration rate (eGFR).[38] Type 2 diabetes was defined as a FPG level 
of ≥ 7.0 mmol/l, a nonfasting glucose level of ≥11.1 mmol/l or use of antidiabetic medication 
according to self‐report or to pharmacy data.[39]  
 
2.3. Ascertainment of outcomes 
We included first-onset cardiovascular outcomes that occurred from study enrollment through to 
01 January 2011. Composite CVD was the primary outcome for this analysis, with CHD and stroke 
endpoints as subsidiary outcomes. The sources of information on deaths were ascertained by 
computerized data linkage with the Dutch Central Bureau of Statistics. The Dutch national registry of 
hospital discharge diagnoses (PRISMANT) was the source of data on cardiovascular morbidity 
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hospitalizations.[40] Outcome data were coded according to the International Classification of 
Diseases, Ninth Revision (ICD-9) until 01 January 2009; after which ICD-10 codes were used. We 
defined composite CVD as the combined outcomes of acute and subacute ischemic heart disease 
(IHD), acute myocardial infarction (AMI), percutaneous transluminal coronary angioplasty (PTCA) 
or coronary artery bypass grafting (CABG), intracerebral hemorrhage, other intracranial hemorrhage, 
subarachnoid hemorrhage, stenosis or occlusion of the precerebral or cerebral arteries, and other 
vascular interventions such as percutaneous transluminal angioplasty or bypass grafting of aorta. 
Coronary heart disease was defined as fatal or nonfatal IHD, fatal or nonfatal MI, PTCA, and CABG. 
Stroke events were defined as intracerebral hemorrhage, other intracranial hemorrhage, subarachnoid 
hemorrhage, stenosis or occlusion of the precerebral or cerebral arteries, and carotid obstruction.  
 
2.4. Statistical analyses 
We log-transformed values of skewed variables to achieve approximately symmetrical 
distributions. Baseline characteristics were presented as means (standard deviation, SD) or median 
(interquartile range, IQR) for continuous variables and percentages for categorical variables. We 
calculated partial correlation coefficients (adjusted for age and sex) to evaluate the cross-sectional 
associations of plasma NGAL levels with CVD risk markers. Cox proportional hazards regression 
models were used to assess the associations of plasma NGAL with risk of CVD, after confirming no 
major departure from hazards proportionality assumptions using Schoenfeld residuals.[41] We plotted 
cumulative Kaplan-Meier curves for CVD during follow-up according to categories of NGAL. We 
assessed the shape of the association of plasma NGAL with CVD risk by plotting hazard ratios (HRs) 
calculated within quartiles of baseline NGAL values (relative to the bottom quartile) against the mean 
NGAL value in each quartile using floating absolute risks (FARs).[42] As the association showed a 
non-linear shape, NGAL was categorised as fourths defined according to its baseline distribution. 
Because of the relatively flat risk of CVD across quartiles 1-2, these categories were combined and 
served as the reference comparison. In a subsidiary analysis, quartile 2 was used as the reference 
comparison. Hazard ratios were calculated with adjustment for confounders in four models: i) age and 
sex; ii) smoking status, history of type 2 diabetes, systolic blood pressure (SBP), total cholesterol, and 
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HDL-C; iii) other potential confounders [triglycerides, body mass index (BMI), alcohol consumption, 
FPG, and hsCRP]; and iv) UAE and eGFR. We explored if the association is modified by relevant 
clinical characteristics using tests of interaction. Finally, we conducted sensitivity analyses which 
employed the use of complex survey design analyses;[43] this is to take into account that the 
PREVEND cohort is oversampled for subjects with higher albuminuria levels, which enables the 
results to be extrapolated to the broader (general) population. All statistical analyses were conducted 
using Stata version 14 (Stata Corp, College Station, Texas). 
 
3. Results 
3.1. Baseline characteristics 
Baseline characteristics of study participants are presented in Table 1. Overall, mean age of 
participants at study entry was 53 (SD, 12) years and 47.8% were men. There were significant 
differences in baseline characteristics between participants who did and did not develop CVD. 
Participants who developed CVD at follow-up were more likely to be older; be smokers; have a 
history of type 2 diabetes; be using antihypertensive and lipid-lowering medications; have higher BMI 
and blood pressure; have higher circulating NGAL, total cholesterol, triglycerides and lower HDL-C 
levels; have higher levels of markers of inflammation and metabolic function; and have lower renal 
function at study entry compared with those who did not develop CVD. The mean (SD) plasma 
concentration of NGAL was 105.8 (37.2) µg/L. NGAL was weakly correlated with several risk 
markers: positively with age, triglycerides, hsCRP, creatinine, and UAE; and inversely with HDL-C 
and FPG. Moderately strong correlations were observed for cystatin C (r=0.41) and eGFR (r=-0.34). 
Baseline NGAL concentrations were higher by 5.65% in males compared with females, by 13.49% in 
current smokers compared with never and former smokers, and by 5.32% in subjects on 
antihypertensive medication compared with non-users. The levels were lower by 4.07% in subjects 
with type 2 diabetes compared to those without type 2 diabetes (Table 2).  
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3.2. Plasma NGAL and risk of incident CVD 
A total of 338 incident CVD events (annual rate 8.21/1,000 person-years at risk; 95% CI: 7.38 to 
9.14) were recorded during a median follow-up of 8.3 (IQR, 7.7-8.9) years. Cumulative hazard curves 
showed an increased risk of CVD in the top quartile of NGAL levels compared with quartiles 1-2 and 
3 (P-value for log-rank test < 0.001 for all; Figure 1). In analyses adjusted for age and sex and also 
for conventional risk factors, a non-linear relationship was observed between NGAL and CVD risk 
(Figure 2). Table 3 reports the associations of plasma NGAL with the risk of CVD outcomes in 
analyses that compared the top quartile versus bottom quartiles 1-2 of the NGAL distribution. The 
age- and sex-adjusted HR for CVD was 1.48 (95% CI: 1.15 to 1.91), which was minimally attenuated 
to 1.35 (95% CI: 1.05 to 1.75) following further adjustment for conventional CVD risk factors. 
However, further adjustment for loge triglycerides, BMI, alcohol consumption, FPG, and loge hsCRP 
attenuated the association to 1.20 (95% CI: 0.92 to 1.57). The non-significant association was 
considerably attenuated following further adjustment for loge UAE and eGFR 1.05 (95% CI: 0.79 to 
1.40). In an age- and sex-adjusted analysis, the NGAL-CVD association was abrogated after single 
additional adjustment for loge hsCRP 1.21 (95% CI: 0.93 to 1.57) and eGFR 1.26 (95% CI: 0.96 to 
1.66). The associations were non-significant for CHD and stroke (Table 3). All results were 
essentially similar when design-based Cox regression analyses were conducted (Table 4). In 
subsidiary analysis that compared the top quartile versus quartile 2 of the NGAL distribution, the 
associations were qualitatively similar (Table 5). The association between NGAL and CVD risk did 
not vary significantly by levels or categories of several clinically relevant characteristics and other 
risk markers (P for interaction ≥ 0.10 for each; Figure 3). 
 
4. Discussion 
4.1. Main findings 
In this large-scale population-based study of Caucasian males and females without a history of 
CVD at study entry, baseline NGAL levels were generally weakly correlated with several 
cardiovascular risk markers. Moderately strong correlations were observed with measures of renal 
function. Characterization of the shape of the association showed a non-linear relationship between 
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NGAL and CVD risk. The association which was independent of conventional risk factors and other 
potential confounders, was attenuated on accounting for inflammation and renal function. The 
association was not modified by clinically relevant subgroups and remained persistent in analyses that 
took into account that the PREVEND cohort is oversampled for subjects with higher albuminuria 
levels. There was no evidence of associations of NGAL with CHD or stroke endpoints; findings 
which might be attributed to the low event rates. Further work is required to explore the associations 
of NGAL with these outcomes.  
 
4.2. Comparison with previous work 
In 1,393 community-dwelling older adults of the Rancho Bernardo Study (RBS) who were 
followed for an average period of 11 years, Daniels and colleagues demonstrated NGAL to be 
independently associated CVD mortality as well as composite CVD. The association was also 
independent of renal function (as measured by creatinine clearance), N-terminal pro B-type natriuretic 
peptide (NT-proBNP), and CRP.[25] NGAL was also demonstrated to add prognostic value on top of 
established cardiovascular risk factors and biomarkers such as NT-proBNP and CRP. Lindberg and 
colleagues also reported similar findings in the fourth Copenhagen Heart Study (CHS) of 5,599 
community dwelling men and women followed for an average period of 10 years.[24] Unlike findings 
of these previous studies which were also based in general population settings, our results show that 
the association between NGAL and CVD risk is dependent on inflammation as well as renal function. 
The inconsistencies in the findings could be related to differences in sample sizes; population 
characteristics such as age or presence of undiagnosed pre-existing disease at baseline; sample storage 
and assay methods for NGAL measurements; distribution of NGAL; or outcomes. For example, 
though the sample sizes and age distribution of participants for the PREVEND cohort and fourth CHS 
were similar, the RBS was based on a relatively smaller sample size of elderly participants. The 
stronger and independent associations demonstrated in RBS participants could be a consequence of 
selection bias, associated with the inclusion of individuals who may already be at increased risk of 
CVD. Indeed, stronger associations have been observed between NGAL and cardiovascular mortality 
in individuals with pre-existing CVD.[44] NGAL was normally distributed in the PREVEND cohort, 
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whiles the distribution was skewed in the RBS and fourth CHS cohorts.[24, 25] Since plasma NGAL 
levels in a healthy population mainly reflects inflammation,[24] it is possible that the skewed 
distribution of plasma NGAL in these cohorts could reflect an over-inclusion of participants with low-
grade inflammation, hence the stronger associations which were independent of inflammation. 
Though previous studies also involved prolonged sample storage at -70 or -80 °C, there is a 
possibility that storage as well as freeze/thawing methods in the PREVEND study could have 
contributed to the weak associations demonstrated in our analyses due to sample degradation. 
Evidence on whether plasma NGAL is influenced by prolonged storage for several years is sparse; 
however, plasma NGAL has been shown to be stable using repeated freeze-thaw cycles and can 
remain stable for at least 11 months at -80 °C.[45, 46] In the PREVEND study, assay methods 
employed a particle-enhanced turbidimetric immunoassay for NGAL not calibrated to the commercial 
available standardized point-of-care assay – Triage® NGAL test – which provides non-biased 
measurements of plasma NGAL.[1] The fourth CHS used an in-house time resolved 
immunofluorometric assay based on NGAL antibodies, whiles the RBS used a competitive 
immunoassay developed on the Luminex platform, which was also not calibrated to the commercial 
available assay. Finally, there was a difference in outcome between the PREVEND cohort and fourth 
CHS. The fourth CHS evaluated major adverse cardiovascular events which comprised of mortality or 
hospitalization due to AMI, ischemic stroke or heart failure; however, the PREVEND study did not 
include heart failure in the CVD outcome definition, but in addition included IHD, PTCA or CABG, 
intracerebral hemorrhage, other intracranial hemorrhage, subarachnoid hemorrhage, and other 
vascular interventions such as percutaneous transluminal angioplasty or bypass grafting of aorta. 
Our findings also provide new observations previously not reported in the general population 
setting – we showed a non-linear shape to the association and therefore appropriately modelled 
NGAL as a categorical variable compared to previous studies that assumed a linear relationship to the 
association. Consistent with our findings, in a prospective evaluation of patients undergoing coronary 
angiography in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study, a U-shaped 
relationship was demonstrated between NGAL and mortality (cardiovascular and all-cause 
mortality).[23] Furthermore in their findings, the association was abrogated on further adjustment for 
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eGFR. Interestingly, the LURIC study employed NGAL assay methods which were similar to that of 
the PREVEND study. Finally, in a comprehensive subgroup analyses, we also demonstrated that the 
NGAL-CVD association was not modified by relevant clinical characteristics such as age, sex, levels 
or categories of other cardiovascular risk factors, inflammation, and renal function.  
 
4.3. Possible explanations for findings  
NGAL has multiple functions beyond its well-known property as a marker of renal function. 
Accumulating evidence provides biological plausibility for the potential role of NGAL in CVD 
development. Evidence from both human studies and animal models have shown NGAL to be highly 
expressed in thrombi and atherosclerotic plaques,[11-14] suggesting that NGAL may be involved in 
the atherosclerotic process. NGAL is highly expressed in the heart with suggestion of a potential role 
in the pathogenesis of myocarditis.[47] NGAL has been demonstrated to co-localize with matrix 
metalloproteinase (MMP)-9 in the cytosol and lipid core of atherosclerotic plaques;[10, 11, 14] MMP-
9 is an important mediator of atherosclerosis, plaque instability and vascular remodeling.[48, 49] 
Evidence suggests the presence of NGAL inhibits the degradation of MMP-9 resulting in the 
preservation of its enzymatic activity[50] and the NGAL-MMP-9 interaction is relevant to the 
development of atherosclerotic plaques and CHD.[51] NGAL mediates inflammatory response[52] 
and is upregulated in inflammatory vascular damage,[53] suggesting its role in atherosclerotic CVD 
via inflammatory processes. Indeed, the association between NGAL and CVD was abrogated on 
further adjustment for hsCRP, lending further support to the inflammation hypothesis of 
atherosclerotic CHD development. NGAL is also upregulated in endothelial dysfunction, which plays 
an important role in CVD development.[54] Whether NGAL plays a direct role in the etiology of 
CVD or may just be a marker of underlying pathology is uncertain. Further clarification of the role of 
NGAL in the pathogenesis of CVD is required in mechanistic studies. 
 
4.4. Implications of findings 
Irrespective of the dependence on the association between NGAL and CVD risk on inflammation 
and renal function; the current findings are relevant and may have implications for CVD prevention. 
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Findings suggest that elevated circulating levels are associated with an increased risk of future CVD. 
Whether NGAL is just a risk marker for CVD, an emerging cardiovascular risk factor, or causal 
therapeutic target, remains to be ascertained. However, the current findings suggest that NGAL may 
be a risk marker for CVD. In the absence of evidence establishing a potential relevance of circulating 
NGAL in CVD prevention strategies, individuals with elevated NGAL levels may need clinical 
evaluation of their cardiovascular risk. 
 
4.5. Strengths and limitations 
The notable strengths of the current study include the large sample size of participants who were  
identified from population registers and were representative of the general population; the follow-up 
for ascertainment of outcomes was long; there was information on a comprehensive panel of lifestyle 
and biological markers which enabled adequate adjustment for relevant potential confounding; the 
design minimized possibilities of reverse causation bias as it involved individuals free of vascular 
disease or malignant disorders at baseline; and the analysis was comprehensive which included 
characterization of the shape of the association, evaluation of effect modification, and sensitivity 
analyses. The limitations of the current study also deserve consideration. As with observational cohort 
designs, there was potential for residual confounding due to errors in confounder measurements 
and/or other unmeasured covariates. The findings were demonstrated in white European Caucasians 
and therefore cannot be generalized to other ethnicities. NGAL was measured at only one point in 
time, which precluded the ability to correct for regression dilution bias and this could have 
underestimated the associations demonstrated. We had no data on urine NGAL which precluded 
assessment of its associations with CVD as well as comparisons with plasma NGAL. Non-biased 
measurements of urine NGAL are obtained using the standardized ARCHITECT immunoassay 
platform (ARCHITECT® analyzer, Abbot Diagnostics) and are also not cumbersome to perform just 
like the Triage® NGAL assay for plasma NGAL. However, urine NGAL measurements require more 
time (within 35 min) compared to plasma NGAL (15 min).[1] Given that circulating NGAL may be 
mainly derived from activated neutrophils whiles urine NGAL may be tubular epithelial cells 
derived,[44] it has been suggested that urine NGAL may be a more robust indicator of AKI compared 
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with plasma NGAL. Whether urine or plasma NGAL is a more robust indicator of CVD risk is 
uncertain, as there is limited evidence on comparative studies. In a cohort of 597 Swedish men aged 
78 years who were followed up for a median period of 8.1 years, urine NGAL was shown to be 
associated with CVD and all-cause mortality independently of cardiovascular risk factors including 
eGFR and CRP; however, serum NGAL was not independently associated with both outcomes in the 
same study population.[44] In this same study, no significant correlation was demonstrated between 
serum and urine NGAL. The authors suggest that these findings might reflect the different origins of 
serum and urine NGAL. Daniels and colleagues in their report of the RBS indicated that the potential 
role of plasma NGAL in the development of CVD may be the distinguishing characteristic between 
plasma NGAL and urine NGAL.[25] However, in their analyses, no comparisons were made with 
urine NGAL. Among 3,386 patients with CKD, urine NGAL was shown to be independently 
associated with the risk of future ischemic atherosclerotic events, but not with heart failure or all-
cause mortality.[55] In another study of 2,466 patients with CKD, among which 34% had a self-
reported history of any CVD, urine NGAL was associated with all-cause mortality but not with heart 
failure or atherosclerotic CVD.[22] Further large-scale studies are needed to robustly compare the 
associations of plasma and urine NGAL with cardiovascular outcomes and evaluate their potential 
utility in predicting risk.  
In conclusion, in a predominantly Caucasian population, plasma NGAL is associated with an 
increased risk of CVD in a non-linear fashion. The association is independent of established risk 
factors but is dependent on inflammation and renal function.  
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Table 1. Baseline participant characteristics overall and according to cardiovascular disease 
development 
 Overall  
(N=5275) 
Mean (SD) or median 
(IQR) or n (%) 
Without CVD 
(N=4937) 
Mean (SD) median 
(IQR) or n (%) 
With CVD  
(N=338) 
Mean (SD) or median 
(IQR) or n (%) 
P-value 
     
Plasma NGAL (µg/L) 105.8 (37.2) 104.9 (35.7) 118.5 (52.5) < 0.001 
     
Questionnaire     
Male 2519 (47.8) 2278 (46.1) 241 (71.3) < 0.001 
Age at survey (years) 53 (12) 52 (12) 63 (11) < 0.001 
History of type 2 diabetes 281 (5.3) 239 (4.8) 42 (12.4) < 0.001 
Current smokers 1448 (27.5) 1337 (27.1) 111 (32.8) < 0.001 
Alcohol consumers 3988 (75.6) 3756 (76.1) 232 (68.6) 0.002 
Use of anti-hypertensive 
medication 
770 (15.5) 658 (14.2) 112 (34.2) < 0.001 
Use of lipid-lowering medication 125 (2.9) 104 (2.6) 21 (7.0) < 0.001 
     
Physical measurements     
BMI (kg/m2) 26.5 (4.3) 26.4 (4.3) 27.7 (3.9) < 0.001 
SBP (mmHg) 125 (18) 124 (18) 140 (20) < 0.001 
DBP (mmHg) 73 (9) 73 (9) 79 (9) < 0.001 
     
Lipid markers     
Total cholesterol (mmol/l) 5.47 (1.04) 5.45 (1.04) 5.77 (1.10) < 0.001 
HDL-C (mmol/l) 1.27 (0.31) 1.28 (0.31) 1.16 (0.29) < 0.001 
Triglycerides (mmol/l) 1.11 (0.80-1.59) 1.09 (0.79-1.57) 1.33 (0.98-1.87) < 0.001 
     
Metabolic, inflammatory, and 
renal function markers 
    
hsCRP (mg/l) 1.30 (0.61-2.89) 1.25 (0.59-2.79) 2.24 (1.05-4.73) < 0.001 
Fasting plasma glucose (mmol/l) 5.00 (1.10) 4.97 (1.07) 5.37 (1.42) <0.001 
Creatinine (µmol/l) 71.0 (62.0-80.0) 71.0 (62.0-79.0) 76.0 (67.0-89.0) < 0.001 
Cystatin C (mg/l) 8.99 (1.99) 8.89 (1.82) 10.39 (3.39) < 0.001 
eGFR (ml/min/1.73 m2) 85 (10) 85 (9) 77 (15) < 0.001 
    eGFR < 60 ml/min/1.73 m2* 198 (3.9) 147 (3.0) 51 (15.1) <0.001 
    eGFR < 90 ml/min/1.73 m2* 2131 (40.4) 1907 (38.6) 224 (66.3) < 0.001 
UAE (mg/24 hours) 8.43 (6.00-14.89) 8.27 (5.94-14.22) 13.29 (7.82-36.21) < 0.001 
Continuous variables are reported as mean ± SD or median (interquartile range) and categorical variables are reported as n (%); *, reported 
as n (%); BMI, body mass index;  DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using the Chronic 
Kidney Disease Epidemiology Collaboration  combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; 
hsCRP, high sensitivity C-reactive protein; IQR, interquartile range;  NGAL, neutrophil gelatinase-associated lipocalin; SBP, systolic blood 
pressure; SD, standard deviation; UAE, urinary albumin secretion 
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Table 2. Cross-sectional correlates of plasma NGAL 
 
Partial correlation 
r (95% CI)† 
Percentage difference (95% CI) in NGAL levels 
per 1 SD higher or compared to reference 
category of correlate‡ 
   
Plasma NGAL (µg/L) - - 
   
Sex   
    Female - Ref 
    Male - 5.65% (3.65, 7.65)*** 
   
Questionnaire   
Age at survey (years) 0.05 (0.03, 0.08)*** 2.01% (1.01, 3.01)*** 
History of type 2 diabetes   
    No - Ref 
    Yes - -4.07% (-8.59, 0.46) 
Smoking status   
    Never and former smokers - Ref 
    Current smokers - 13.49% (11.27, 15.71)*** 
Alcohol consumption   
    Non-consumers - Ref 
    Current consumers - -0.94% (-3.31, 1.43) 
Use of anti-hypertensive medication   
    No - Ref 
    Yes - 5.32% (2.29, 8.35)** 
Use of lipid-lowering medication   
    No  Ref 
    Yes  3.07% (-3.62, 9.76) 
   
Physical measurements   
BMI (kg/m2) 0.00 (-0.02, 0.03) 0.13% (-0.90, 1.15) 
SBP (mmHg) 0.01 (-0.02, 0.04) 0.41% (-0.74, 1.57) 
DBP (mmHg) -0.02 (-0.05, 0.01) -0.83% (-1.94, 0.27) 
   
Lipid markers   
Total cholesterol (mmol/l) -0.03 (-0.06, -0.01)* -1.31% (-2.34, -0.29)* 
HDL-C (mmol/l) -0.10 (-0.13, -0.08)*** -4.24% (-5.34, -3.15)*** 
Triglycerides (mmol/l) 0.04 (0.02, 0.07)*** 1.63% (0.62, 2.64)* 
   
Metabolic, inflammatory, and renal function 
markers 
  
hsCRP (mg/l) 0.29 (0.26, 0.31)*** 11.05% (10.07, 12.04)*** 
Fasting plasma glucose (mmol/l) -0.07 (-0.09, -0.04)* -2.54% (-3.57, -1.51)*** 
Creatinine (µmol/l) 0.26 (0.24, 0.29)*** 11.47% (10.33, 12.62)*** 
Cystatin C (mg/l) 0.41 (0.38, 0.43)*** 16.87% (15.85, 17.90)*** 
eGFR (ml/min/1.73 m2) -0.34 (-0.37, -0.32)*** -15.33% (-16.47, -14.19)*** 
Loge UAE (mg/24 hours) 0.12 (0.10, 0.15)*** 4.74% (3.71, 5.78)*** 
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using the Chronic Kidney 
Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; hsCRP, high-
sensitivity C-reactive protein; NGAL, neutrophil gelatinase-associated lipocalin; Ref, reference; SD, standard deviation; SBP, systolic blood 
pressure; UAE, urinary albumin secretion 
Asterisks indicate the level of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001; †Partial correlation coefficients between NGAL and the row 
variables; ‡Percentage change in NGAL levels per 1 SD increase in the row variable (or for categorical variables, the percentage difference in mean NGAL 
levels for the category versus the reference) adjusted for age and sex. 
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Table 3. Prospective association of NGAL with risk of cardiovascular disease outcomes 
NGAL Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Cardiovascular disease 
Q1 – Q2 131 / 2639 ref  ref  ref  ref  
Q3 89 / 1319 1.30 (0.99 to 1.71) 0.055 1.24 (0.95 to 1.63) 0.118 1.18 (0.90 to 1.56) 0.229 1.13 (0.85 to 1.49) 0.400 
Q4 118 / 1317 1.48 (1.15 to 1.91) 0.002 1.35 (1.05 to 1.75) 0.022 1.20 (0.92 to 1.57) 0.176 1.05 (0.79 to 1.40) 0.745 
Coronary heart disease 
Q1 – Q2 99 / 2639 ref  ref  ref  ref  
Q3 66 / 1319 1.27 (0.93 to 1.74) 0.130 1.24 (0.90 to 1.70) 0.181 1.21 (0.88 to 1.67) 0.236 1.16 (0.84 to 1.60) 0.369 
Q4 80 / 1317 1.32 (0.98 to 1.78) 0.067 1.20 (0.89 to 1.63) 0.234 1.12 (0.82 to 1.54) 
54 
0.473 0.99 (0.70 to 1.39) 0.938 
Stroke 
Q1 – Q2 36 / 2639 ref  ref  ref  ref  
Q3 21 / 1319 1.14 (0.66 to 1.95) 0.641 1.07 (0.62 to 1.84) 0.819 0.98 (0.57 to 1.70) 0.948 0.95 (0.54 to 1.66) 0.854 
Q4 34 / 1317 1.56 (0.97 to 2.52) 0.067 1.48 (0.91 to 2.40) 0.114 1.17 (0.71 to 1.94) 0.536 1.07 (0.62 to 1.86) 0.799 
 
CI, confidence interval; HR, hazard ratio; NGAL, neutrophil gelatinase-associated lipocalin 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of type 2 diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol 
Model 3: Model 2 plus triglycerides, body mass index, alcohol consumption, glucose, and loge high sensitivity C-reactive protein 
Model 4: Model 3 plus loge urinary albumin excretion and estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined 
creatinine-cystatin C equation) 
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Table 4 Prospective association of NGAL with risk of cardiovascular disease outcomes using complex survey analyses 
NGAL Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Cardiovascular disease 
Q1 – Q2 131 / 2639 ref  ref  ref  ref  
Q3 89 / 1319 1.27 (0.95 to 1.70) 0.107 1.19 (0.88 to 1.61) 0.249 1.14 (0.84 to 1.54) 0.414 1.06 (0.77 to 1.45) 0.724 
Q4 118 / 1317 1.53 (1.17 to 2.01) 0.002 1.36 (1.04 to 1.80) 0.027 1.21 (0.91 to 1.61) 0.194 0.99 (0.73 to 1.35) 0.960 
Coronary heart disease 
Q1 – Q2 99 / 2639 ref  ref  ref  ref  
Q3 66 / 1319 1.24 (0.88 to 1.73) 0.218 1.20 (0.85 to 1.69) 0.312 1.17 (0.82 to 1.66) 0.379 1.09 (0.76 to 1.57) 0.624 
Q4 80 / 1317 1.28 (0.92 to 1.78) 0.136 1.14 (0.82 to 1.60) 0.437 1.07 (0.75 to 1.51) 
54 
0.721 0.86 (0.59 to 1.27) 0.459 
Stroke 
Q1 – Q2 36 / 2639 ref  ref  ref  ref  
Q3 21 / 1319 1.14 (0.64 to 2.02) 0.653 1.06 (0.59 to 1.90) 0.852 1.01 (0.55 to 1.84) 0.976 0.97 (0.53 to 1.79) 0.922 
Q4 34 / 1317 1.74 (1.05 to 2.86) 0.030 1.64 (0.98 to 2.73) 0.059 1.36 (0.78 to 2.37) 0.280 1.21 (0.68 to 2.15) 0.512 
 
CI, confidence interval; HR, hazard ratio; NGAL, neutrophil gelatinase-associated lipocalin 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of type 2 diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol 
Model 3: Model 2 plus triglycerides, body mass index, alcohol consumption, glucose, and loge high sensitivity C-reactive protein 
Model 4: Model 3 plus loge urinary albumin excretion and estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined 
creatinine-cystatin C equation) 
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Table 5 Prospective association of NGAL with risk of cardiovascular disease outcomes (with quartile 2 of NGAL distribution as reference comparison) 
NGAL Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value 
Cardiovascular disease 
Q1 70 / 1326 1.20 (0.85 to 1.69) 0.308 1.21 (0.85 to 1.70) 0.286 1.21 (0.86 to 1.71) 0.273 1.23 (0.87 to 1.74) 0.240 
Q2 61 / 1313 ref  ref  ref  ref  
Q3 89 / 1319 1.43 (1.03 to 1.98) 0.032 1.37 (0.98 to 1.89) 0.062 1.30 (0.94 to 1.81) 0.114 1.25 (0.90 to 1.74) 0.191 
Q4 118 / 1317 1.62 (1.19 to 2.22) 0.002 1.48 (1.08 to 2.03) 0.014 1.32 (0.96 to 1.82) 0.088 1.16 (0.83 to 1.62) 0.396 
Coronary heart disease 
Q1 47 / 1326 1.08 (0.73 to 1.60) 0.713 1.09 (0.73 to 1.62) 0.677 1.09 (0.73 to 1.62) 0.673 1.07 (0.72 to 1.59) 0.753 
Q2 52 / 1313 ref  ref  ref  ref  
Q3 66 / 1319 1.32 (0.91 to 1.93) 0.145 1.30 (0.89 to 1.90) 0.181 1.27 (0.86 to 1.86) 0.224 1.20 (0.81 to 1.77) 0.358 
Q4 80 / 1317 1.37 (0.95 to 1.98) 0.088 1.26 (0.87 to 1.83) 0.227 1.17 (0.80 to 1.72) 0.409 1.02 (0.68 to 1.54) 0.917 
Stroke 
Q1 23 / 1326 0.56 (0.28 to 1.11) 0.097 0.56 (0.28 to 1.11) 0.095 0.54 (0.27 to 1.08) 0.080 0.54 (0.27 to 1.07) 0.076 
Q2 13 / 1313 ref  ref  ref  ref  
Q3 21 / 1319 0.88 (0.49 to 1.60) 0.686 0.82 (0.45 to 1.50) 0.526 0.75 (0.41 to 1.37) 0.349 0.72 (0.39 to 1.33) 0.288 
Q4 34 / 1317 1.21 (0.71 to 2.08) 0.485 1.14 (0.65 to 1.98) 0.646 0.89 (0.50 to 1.57) 0.688 0.80 (0.43 to 1.49) 0.479 
 
CI, confidence interval; HR, hazard ratio; NGAL, neutrophil gelatinase-associated lipocalin 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of type 2 diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol 
Model 3: Model 2 plus triglycerides, body mass index, alcohol consumption, glucose, and loge high sensitivity C-reactive protein 
Model 4: Model 3 plus loge urinary albumin excretion and estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined 
creatinine-cystatin C equation) 
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Figure legends 
Figure 1 Cumulative Kaplan-Meier curves for cardiovascular disease during follow-up according to 
quartiles of NGAL 
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CVD, cardiovascular disease; NGAL, Neutrophil gelatinase-associated lipocalin 
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Figure 2 Hazard ratios for incident cardiovascular disease, by baseline concentrations of plasma 
NGAL using floating absolute risks 
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A, Hazard ratios were adjusted for age and sex; B, adjustment in A plus smoking status, history of 
type 2 diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol 
NGAL, Neutrophil gelatinase-associated lipocalin 
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Figure 3 Hazard ratios for NGAL and cardiovascular disease risk by several participant level 
characteristics 
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Hazard ratios were adjusted for age, sex, smoking status, history of type 2 diabetes, systolic blood 
pressure, total cholesterol, and high-density lipoprotein-cholesterol; CI, confidence interval (bars); 
CVD, cardiovascular disease; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HR, 
hazard ratio; hs, high sensitivity; NGAL, Neutrophil gelatinase-associated lipocalin 
*, P-value for interaction; cut-offs used for fasting glucose, body mass index, systolic blood pressure, 
total cholesterol, HDL-cholesterol, hsCRP, creatinine, and cystatin C are median values. 
 
  
